InvestorsHub Logo
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 4848

Thursday, 07/28/2022 9:24:09 AM

Thursday, July 28, 2022 9:24:09 AM

Post# of 6093
PFE 2Q22 results—2022 guidance for Comirnaty and Paxlovid remain $32B and $22B, respectively:

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-second-quarter-2022-results

2022 non-GAAP EPS guidance is now $6.30-6.45 (from the prior range of $6.25-6.45), despite an increased headwind of $0.24/sh from currency exchange rates (i.e. the strong US dollar).


CC slides:
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf

Transcript of CC prepared remarks:
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PFE News